← FDA DRUG APPROVALS

FDA NDA · NDA017971

ESKALITH

Sponsor: JDS PHARMS

APPLICATION
NDA017971
TYPE
NDA
ORIGINAL APPROVAL
1979-02-26
LATEST ACTION
2004-03-11
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

ESKALITHDiscontinued
LITHIUM CARBONATE 300MG · TABLET · ORAL

Approval history

2004-03-11Supplement · Supplement 20 · standardLabelAP
1987-07-29Manufacturing (CMC) · Supplement 10 · standardAP
1983-01-27Labeling · Supplement 9AP
1982-04-29Labeling · Supplement 8AP
1981-12-02Labeling · Supplement 7AP
1981-11-24Labeling · Supplement 6AP
1981-09-11Labeling · Supplement 5AP
1980-09-19Labeling · Supplement 3AP
1980-02-06Labeling · Supplement 2AP
1979-09-20Labeling · Supplement 1AP
1979-02-26Type 5 - New Formulation or New Manufacturer · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →